Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05636904
Other study ID # DLQ01-001
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date December 5, 2022
Est. completion date March 28, 2024

Study information

Verified date April 2024
Source Dermaliq Therapeutics, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this study is to measure the safety, tolerability, and the hair growth response to topical DLQ01 solutions in comparison to the vehicle and a comparator solution in 120 males with Androgenetic Alopecia.


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date March 28, 2024
Est. primary completion date March 28, 2024
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Males with active AGA on the vertex area of the scalp consistent with Norwood-Hamilton Grades of IIIv through V, excluding IIIa, IVa, and Va grades. - Willing to maintain the same hair style, approximate length, and hair colour throughout the duration of the study as documented in the global photograph at Day -2 of baseline. - Willing to have target areas shaved and to have temporary dot tattoos placed on their scalp. - Willing to comply with the study instructions and return to the site for required visits. - Must be willing and able to communicate and participate in the entire study and willing to use an electronic diary to record investigational product dosing. - Must provide written informed consent. Exclusion Criteria: - Participants with other type of alopecia other than AGA or any other concomitant skin or systemic disorder involving the scalp area. - Participants with sensitive, irritated, or abraded scalp area. - Participants who have undergone hair transplants or have had scalp reductions. - Concurrent treatments or interventions that could affect interpretation of study data, prior to or during the study, as specified in the protocol - Current evidence of another ongoing or acute relevant cutaneous infection, active systemic infection, or other significant skin conditions. - History of relevant sensitivity to any of the study products, or components thereof, or a history of drug or other allergy that contraindicates study participation. - Known allergy or sensitivity to tattoo ink. - Participant with relevant active or prior history of malignancies. - Participants with relevant cardiovascular disease including ischemic heart disease, cardiac arrhythmias, or congestive heart disease. - History of any relevant alcoholism, substance or drug abuse-related disorders in the past year or a positive toxicology screening panel, or alcohol breath test at Screening. - Clinically significant abnormal biochemistry, haematology or urinalysis values. - Any other relevant serious illness or medical, physical, or psychiatric condition(s) that, could interfere with full participation in the study, pose a significant risk to the participant; or interfere with interpretation of study data.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
prostaglandin F2a analogue in vehicle solution high dose
Topical treatment for 24 weeks
prostaglandin F2a analogue in vehicle solution low dose
Topical treatment for 24 weeks
active ingredient-free vehicle solution to DLQ01
Topical treatment for 24 weeks
Minoxidil 5% Topical Solution
Topical treatment for 24 weeks

Locations

Country Name City State
Australia Dr Rodney Sinclair Pty Ltd, East Melbourne Victoria
Australia Dr Rodney Sinclair Pty Ltd, Pascoe Vale South Victoria

Sponsors (1)

Lead Sponsor Collaborator
Dermaliq Therapeutics, Inc.

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary TAHC (total, terminal, and vellus) Change from baseline in total, terminal, and vellus target area hair counts (TAHC) using digital image analysis after 4, 12, and 24 weeks of treatment, and at the follow-up visit 28 weeks
Primary Cumulative hair thickness density (mm/cm2) Change in cumulative hair thickness density using digital image analysis after 4, 12, and 24 weeks of treatment, and at the follow-up visit. 28 weeks
Primary Anagen/telogen ratio Change in anagen/telogen ratios using digital image analysis after 4, 12, and 24 weeks of treatment, and at the follow-up visit. 28 weeks
Secondary Investigator global assessment (IGA) using a 7-point ordinal scale compared to baseline Investigator assessment of the participant´s scalp hair growth compared to baseline using the following 7-point scale: greatly decreased (-3), moderately decreased (-2), slightly decreased (-1), no change (0), slightly increased (1), moderately increased (2), and greatly increased (3) compared to baseline at 4, 12, 16, and 24 weeks of treatment, and at the follow-up visit 28 weeks
Secondary Frequency of scores for cutaneous reactions in the treated area through study day 194 Investigator assessment of cutaneous reactions such as erythema, oedema, glazing with fissures, vesicles, or papules, by grading with a clinical 5-point scale: no irritation (0), mild (1), moderate (2), severe (3), and very severe (4) at each visit through study day 194 28 weeks
Secondary Frequency of scores for pigmentation changes compared to non-treated area of scalp and hair through study day 194 Investigator assessment of pigmentation changes compared to non-treated area of scalp and hair by grading with a clinical 4-point scale: no difference (0), slight difference, <25% (1), moderate difference, <50 to 75% (2), significantly darker/lighter, <75 to 100% (3) at each visit through study day 194 28 weeks
Secondary Number of participants with clinically significant abnormal laboratory test results Collection of safety blood at screening, after 24 weeks of treatment, and at follow-up 28 weeks
Secondary Number of participants with clinically significant abnormal heart rate Collection of heart rate at screening, baseline, and after 4, 16, and 24 weeks of treatment, and at follow-up 28 weeks
Secondary Number of participants with clinically significant abnormal blood pressure Collection of blood pressure at screening, baseline, and after 4, 16, and 24 weeks of treatment, and at follow-up 28 weeks
Secondary Number of participants with clinically significant abnormal ECG readings Collection of 12-lead ECG at screening, and after 4, 12, 16, and 24 weeks of treatment, and at follow-up 28 weeks
Secondary Plasma concentrations of DLQ01 Blood samples for evaluation of plasma concentrations of active ingredient and novel excipient will be taken at baseline (predose) and after 4, 12 and 24 weeks of treatment 24 weeks
See also
  Status Clinical Trial Phase
Completed NCT02591355 - Evaluate the Clinical Effectiveness of RegenKit Platelet-rich Plasma (PRP) in Androgenetic Alopecia Treatment N/A
Withdrawn NCT03852992 - Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia Phase 2
Recruiting NCT06239207 - Efficacy and Safety of Exosomes Versus Platelet Rich Plasma in Patients of Androgenetic Alopecia Phase 2
Completed NCT04945226 - A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001 Phase 1/Phase 2
Completed NCT01548066 - The Efficacy and Safety of Topical Valproic Acid in Preventing Hair Loss Phase 2
Completed NCT01437163 - Treatment of Androgenetic Alopecia in Males and Females N/A
Completed NCT01226459 - Clinical Trial in Females for Female Pattern Hair Loss Phase 3
Recruiting NCT06118866 - A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia Phase 2
Completed NCT06149221 - Penetration-enhanced Direct DBD Non-thermal Plasma for Hair Loss N/A
Withdrawn NCT04882969 - Thulium Laser and KeraFactor for the Treatment of Androgenetic Alopecia N/A
Completed NCT01231607 - Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia Phase 3
Completed NCT04446429 - Anti-Androgen Treatment for COVID-19 N/A
Completed NCT02729415 - Point-of-Care Adipose-derived Cells for Hair Growth N/A
Completed NCT02279823 - A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia Phase 2
Not yet recruiting NCT01227031 - Pharmacogenomic Study of Androgenetic Alopecia N/A
Completed NCT00981461 - Treatment of Androgenetic Alopecia in Females, 9 Beam N/A
Completed NCT01451021 - A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss Phase 2
Completed NCT00151515 - A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss Phase 3
Completed NCT03694067 - Androgenetic Alopecia and the JAK-STAT Pathway
Completed NCT03689452 - The Effect of Platelet Rich Plasma on Non-scarring Alopecia N/A